Olalekan Oluwole, MBBS, MD - The Time Is Now for Outpatient CAR-T: Essential Infrastructure, Lessons From Transplant, and New Evidence

Go online to PeerView.com/NEC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Although chimeric antigen receptor (CAR-T) cell therapy is primarily administered in the inpatient setting, delivery in the outpatient setting likely represents a more convenient and patient-friendly approach that could expand potentially life-saving treatment access for many patients with hematologic cancers. This “Learning Workshop” activity provides learners with the “tools of the trade” for building an outpatient infrastructure that is capable of expanding patient access to CAR-T therapy. Expert panelists discuss the key data supporting CAR-T therapy in hematologic cancers and provide guidance on principles of outpatient cellular therapy, lessons derived from the outpatient experience with stem cell transplantation, and strategies to overcome barriers to patient selection, adverse events, and adequate staffing. Upon completion of this activity, participants should be better able to: Summarize current evidence supporting the integration of CAR-T constructs into the management of hematologic cancers, including in earlier and later lines of care; Cite the infrastructure and design for an outpatient cellular therapy program and the relevant practical experience from home-based transplantation initiatives; Develop strategies for optimal patient selection, staffing, and management of adverse events in the context of an outpatient cellular therapy program; and Employ tools such as quality metrics, telemedicine, and wearable devices in an outpatient cellular therapy program to ensure successful delivery of CAR-T therapy